Editorji is a popular short video news and information platform based in India. It was founded in 2018 by Vikram Chandra, one of India’s leading journalists, and has risen to prominence in the digital news space in a relatively short span of time. The platform is primarily designed for mobile devices, with applications available for Android and iOS.

ABOUT US:

about us editorji

Latest Video News: Editorji provides the latest news video headlines, latest videos clip from India and the World. Get all breaking news videos on Entertainment, Business, Coronavirus, Elections, Politics and more.

Latest Video News, Breaking News, Bollywood, Political, Sports, Business News | Editorji

+91 11 4035 6666 / info@editorji.com
3rd floor, Plot B, Khasara no 360, Sultanpur, New Delhi, Delhi 110030
<a title="mail to us" href="mailto:info@editorji.com">Send Feedback</a>
<a title="Contact Us" href="mailto:info@editorji.com">Contact Us</a>

REACH US

Contact for any questions, suggestions, comments, feedback or advertisement on Editorji.com, we are always looking forward to hearing from you.

Contact Us for Feedback, Suggestions and Advertising 

Editorji content is better experienced in our app.

Ahmedabad-based vaccine manufacturer Zydus Cadila has told the Centre that it could apply for emergency use authorisation for its Covid-19 vaccine ZyCoV-D in the next seven to ten days, reports said citing sources. The vaccine has completed its phase three trials for which around 28,000 volunteers were recruited. Last month, the vaccine manufacturer had said five crore doses of ZyCoV-D are likely to be available by August-September. Apart from adults, Zydus Cadila is also conducting trials of its vaccine candidate among children aged 12-17 years. If approved, ZyCoV-D will be the fourth vaccine to be used in India's Covid-19 vaccination drive after Covishield, Covaxin and Sputnik V. Zydus Cadila's Covid-19 vaccine candidate ZyCoV-D is India's first indigenously developed DNA vaccine candidate and it is to be administered via intradermal injection.

Zydus Cadila to apply for approval of its Covid vaccine in a week

Zydus Cadila to apply for approval of its Covid vaccine,&nbsp;ZyCoV-D in a week, say reports

Zydus Cadila to apply for emergency use authorisation of its&nbsp;Covid&nbsp;vaccine
Vaccine maker will seek approvals for&nbsp;ZyCoV-D in 7-10 days: reports
The vaccine has completed its phase 3 trials with 28,000 volunteers
Company says&nbsp;5 crore doses&nbsp;likely to be available by August-September
Zydus Cadila&nbsp;also conducting trials of vaccine for children aged 12-17 years
If approved, ZyCoV-D will be the 4th vaccine to be used in India
ZyCoV-D is a&nbsp;DNA vaccine and has to be given via&nbsp;intradermal&nbsp;shots

Ahmedabad-based vaccine manufacturer Zydus Cadila has told the Centre that it could apply for emergency use authorisation for its Covid-19 vaccine ZyCoV-D in the next seven to ten days, reports said citing sources. The vaccine has completed its phase three trials for which around 28,000 volunteers were recruited. Last month, the vaccine manufacturer had said five crore doses of ZyCoV-D are likely to be available by August-September. Apart from adults, Zydus Cadila is also conducting trials of its vaccine candidate among children aged 12-17 years. If approved, ZyCoV-D will be the fourth vaccine to be used in India's Covid-19 vaccination drive after Covishield, Covaxin and Sputnik V. Zydus Cadila's Covid-19 vaccine candidate ZyCoV-D is India's first indigenously developed DNA vaccine candidate and it is to be administered via intradermal injection.

Zydus&nbsp;Cadilla has sought approval from the drug regulator to start human trials for its antibody cocktail to treat mild Covid-19.Zydus said the monoclonal antibody cocktail which has been termed&nbsp;ZRC-3308 has been found to be safe and well-tolerated in animal toxicology studies.&nbsp;The therapy is a cocktail of two monoclonal antibodies, which imitates natural antibodies that the body generates to fight off&nbsp;infection.&nbsp;
Regeneron and Roche have got the USFDA&nbsp;nod for the antibody cocktail&nbsp;drug and Cipla&nbsp;is distributing Roche's product in India. Infact the first batch was dispacted&nbsp;earlier this week. On Wednesday the first COVID-19 patient in India who was treated with a monoclonal antibodies cocktail was discharged from a hospital in Haryana

Zydus Cadila seeks human trial approval for Covid-19 antibody cocktail

Zydus&nbsp;Cadilla has sought approval from the drug regulator to start human trials for its antibody cocktail to treat mild Covid-19. Zydus said the monoclonal antibody cocktail which has been termed&nbsp;ZRC-3308 has been found to be safe and well-tolerated in animal toxicology studies.&nbsp;The therapy is a cocktail of two monoclonal antibodies, which imitates natural antibodies that the body generates to fight off&nbsp;infection.&nbsp;
Regeneron and Roche have got the USFDA&nbsp;nod for the antibody cocktail&nbsp;drug and Cipla&nbsp;is distributing Roche's product in India. Infact the first batch was dispacted&nbsp;earlier this week. On Wednesday the first COVID-19 patient in India who was treated with a monoclonal antibodies cocktail was discharged from a hospital in Haryana

Zydus&nbsp;Cadilla has sought approval from the drug regulator to start human trials for its antibody cocktail to treat mild Covid-19. Zydus said the monoclonal antibody cocktail which has been termed&nbsp;ZRC-3308 has been found to be safe and well-tolerated in animal toxicology studies.&nbsp;The therapy is a cocktail of two monoclonal antibodies, which imitates natural antibodies that the body generates to fight off&nbsp;infection.&nbsp;
Regeneron and Roche have got the USFDA&nbsp;nod for the antibody cocktail&nbsp;drug and Cipla&nbsp;is distributing Roche's product in India. Infact the first batch was dispacted&nbsp;earlier this week. On Wednesday the first COVID-19 patient in India who was treated with a monoclonal antibodies cocktail was discharged from a hospital in Haryana

zydus cadilla

Categories